Open AccessPasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease
Author(s) -
Richard A. Feelders,
Christiaan de Bruin,
Alberto M. Pereira,
Johannes A. Romijn,
Romana T. NeteaMaier,
Ad R. Hermus,
Pierre Zelissen,
Ramona van Heerebeek,
Frank H. de Jong,
AartJan van der Lely,
Wouter W. de Herder,
Leo J. Hofland,
Steven W. J. Lamberts
Publication year - 2010
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmc1000094
Subject(s) - pasireotide , cabergoline , medicine , somatostatin receptor , cushing's disease , somatostatin , ketoconazole , endocrinology , somatostatin analogue , adenoma , octreotide , acromegaly , disease , dermatology , hormone , growth hormone , antifungal , prolactin
To the Editor: Cushing's disease, which is caused by an adrenocorticotropin-secreting pituitary adenoma, is associated with increased morbidity and mortality.1 Currently, there is no effective medical therapy for Cushing's disease. However, recent studies identified the somatostatin-receptor subtype 5 and dopamine-receptor subtype 2 as potential therapeutic targets in Cushing's disease.2 Pasireotide is a new somatostatin analogue that binds with high affinity to somatostatin-receptor subtypes 1, 2, and 3, and it especially has high-affinity binding to somatostatin-receptor subtype 5.3 In a recent 15-day pilot study, pasireotide normalized the excretion of urinary free cortisol in 17% of patients with Cushing's disease.4 Cabergoline, a . . .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom